Enthalpic Efficiency of Ligand Binding

被引:44
作者
Ferenczy, Gyoergy G. [1 ]
Keseru, Gyoergy M. [2 ]
机构
[1] Sanofi Aventis CHINOIN, H-1045 Budapest, Hungary
[2] Gedeon Richter Plc, Discovery Chem, H-1103 Budapest, Hungary
关键词
RENIN INHIBITORS; DRUG DISCOVERY; LEAD DISCOVERY; THERMODYNAMICS; MOLECULES; PROTEINS; AFFINITY; DESIGN; SIZE;
D O I
10.1021/ci100125a
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The thermodynamics of ligand protein binding has received much attention recently. In the present contribution we focus on the enthalpic component of binding. The dissociation constant, pK(d), was decomposed into enthalpic and entropic components (pK(d) = pK(H) + pK(S)), and pK(H), defined as pK(H) = Delta H/(2.303.RT) was used to characterize the enthalpy contribution to binding. It was found that the maximal achievable pKH decreases with increasing molecular size. This is in contrast to maximal pKd that increases with molecular size until it achieves a plateau. Size-independent enthalpic efficiency (SIHE) was defined as SIHE = pK(H)/40.HA(0.3), with HA being the number of heavy atoms. SIHE allows a size unbiased comparative binding characterization of compounds. It can find use in hit and lead selection and also in monitoring optimization in drug discovery programs. The physical background of decreasing maximal pK(H) with molecular size is discussed, and its consequences to drug discovery are analyzed. It is concluded that the feasibility of simultaneous optimization of affinity and enthalpy diminishes with increasing molecular size. Consequently, binding thermodynamics considerations are to be applied primarily in hit prioritization and hit-to-lead optimization.
引用
收藏
页码:1536 / 1541
页数:6
相关论文
共 29 条
  • [1] Ligand efficiency indices as guideposts for drug discovery
    Abad-Zapatero, C
    Metz, JT
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (07) : 464 - 469
  • [2] Differences between High- and Low-Affinity Complexes of Enzymes and Nonenzymes
    Carlson, Heather A.
    Smith, Richard D.
    Khazanov, Nickolay A.
    Kirchhoff, Paul D.
    Dunbar, Jarnes B., Jr.
    Benson, Mark L.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (20) : 6432 - 6441
  • [3] FERENCZY GG, 2010, DRUG DISCOV IN PRESS
  • [4] Generation of a set of simple, interpretable ADMET rules of thumb
    Gleeson, M. Paul
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) : 817 - 834
  • [5] Energetics of hydrogen bonding in proteins: A model compound study
    Habermann, SM
    Murphy, KP
    [J]. PROTEIN SCIENCE, 1996, 5 (07) : 1229 - 1239
  • [6] Molecular complexity and its impact on the probability of finding leads for drug discovery
    Hann, MM
    Leach, AR
    Harper, G
    [J]. JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (03): : 856 - 864
  • [7] Ligand efficiency: a useful metric for lead selection
    Hopkins, AL
    Groom, CR
    Alex, A
    [J]. DRUG DISCOVERY TODAY, 2004, 9 (10) : 430 - 431
  • [8] The influence of lead discovery strategies on the properties of drug candidates
    Keserue, Gyoergy M.
    Makara, Gergely M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) : 203 - 212
  • [9] The maximal affinity of ligands
    Kuntz, ID
    Chen, K
    Sharp, KA
    Kollman, PA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (18) : 9997 - 10002
  • [10] Ladbury J., 2007, EUR PHARM REV, V12, P59